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J. Appi Physiol. 77(6): 2675-2680, 1994.—To define some of 
the mechanisms underlying dextran sulfate (DXS)-induced hy-
potension, we investigated the effects of either the plasma kal-
likrein inhibitor des-Pro2-[Arg15] aprotinin (BAY x 4620) or the 
specific bradykinin B2-receptor antagonist Hoe-140 on the hy-
potensive response to DXS. In the first study, anesthetized 
miniature pigs were given DXS alone, DXS plus BAY x 4620 in 
various doses, or saline. As expected, DXS alone produced a 
profound but transient systemic arterial hypotension with a 
concomitant reduction in kininogen. Circulating kinin levels, 
complement fragment des-Arg-C3a, and fibrin monomer were 
all increased. Treatment with BAY x 4620 produced a dose-de-
pendent attenuation of these effects with complete blockade of 
the hypotension as well as the observed biochemical changes at 
the highest dose (360 mg). In a second study, two groups of pigs 
were given either DXS alone or DXS plus Hoe-140. DXS-in-
duced hypotension was completely blocked by Hoe-140 pre-
treatment; however, kininogen was again depleted. We con-
clude, therefore, that DXS-induced hypotension is produced by 
activation of plasma kallikrein that results in the production of 
bradykinin and that liberation of bradykinin and its action on 
B 2 receptors in the vasculature are both necessary and suffi-
cient to produce the observed effects on circulatory pressure. 
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DEXTRAN SULFATE (DXS) is a negatively charged macro-
molecule that has been shown to activate prekallikrein 
(15). As such, it is one of a variety of compounds that are 
able to activate the contact phase of blood coagulation, a 
multifunctional system of proteases that controls vaso-
regulation (via the formation of the potent vasodilator 
bradykinin) and amplifies the humoral inflammatory re-
sponse (via activation of the coagulation, fibrinolysis, 
and complement pathways) (2). 
The essential components of the contact system are 
the zymogen factor XII (Hageman factor), a negatively 
charged surface or macromolecule that induces a change 
in the conformation of factor XII, high-molecular-mass 
kininogen, prekallikrein, and factor XL In this complex, 
factor XII and prekallikrein can activate each other in 
the presence of kininogen, resulting in the cleavage of 
kininogen by kallikrein and the release of bradykinin (2). 
In addition, factor XHa converts factor XI to its active 
form, factor XIa, thereby activating the coagulation cas-
cade. Both the Hageman factor fragment (8) and throm-
bin (13) are able to activate the classical pathway, 
whereas plasma kallikrein can activate the alternative 
pathway (6) of the complement system. Interaction of 
plasma kallikrein, factor XIa, and factor XHa (3) also 
leads to activation of single-chain urokinase-type plas-
minogen activator and of a contact system-dependent 
plasminogen proactivator (1). In their activated form, 
these proteases convert plasminogen to plasmin and are 
considered to be the primary agents involved in intrinsic 
fibrinolysis. Finally, bradykinin and thrombin induce the 
release of tissue-type plasminogen activator from endo-
thelial cells, thereby triggering extrinsic fibrinolysis. 
Because the contact system combines the activation of 
the plasma cascade systems with the release of the hypo-
tensive mediator bradykinin, the system has long been 
implicated in the pathophysiology of septic shock, dis-
seminated intravascular coagulation, and multiple organ 
failure including adult respiratory distress syndrome (14, 
17). In addition, bacterial lipopolysaccharide has been 
shown to activate the contact system in vitro (18), and in 
humans plasma kallikrein has been shown to be acti-
vated during endotoxemia (5). Finally, plasma kallikrein 
inhibitors such as aprotinin (22) or a^-antitrypsin Pitts-
burgh (4) can attenuate the effects of bacterial- or endo-
toxin-induced experimental shock. 
In a previous investigation we found that infusion of 
DXS decreased the amount of uncleaved kininogen 
(kinin-containing kininogen) in pig plasma and reduced 
systemic arterial pressure. Blood pressure returned to 
normal only after kinin-containing kininogen had been 
depleted. Both the cleavage of kininogen and hypoten-
sion were attenuated or blocked by (^ -esterase inhibitor 
and high doses of aprotinin (9), both of which inhibit 
plasma kallikrein, suggesting a role for bradykinin in this 
effect. In rabbits, however, DXS-induced arterial hypo-
tension has been shown to be mediated via the release of 
serotonin from platelets (25), which can be stimulated by 
thrombin, another mediator of the activated contact 
system. 
The present investigation was conducted to clarify the 
mechanism of DXS-induced hypotension in pigs. It was 
our hypothesis that DXS-induced hypotension is pri-
marily mediated by bradykinin and that other mediators 
such as serotonin, platelet-activating factor, and metabo-
lites of arachidonic acid, if involved, are dependent on 
bradykinin. Two studies were performed, one with the 
plasma kallikrein inhibitor des-Pro2-[Arg15] aprotinin 
(BAY x 4620) (7) and the second with the dekapeptide 
D-Arg°[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (Hoe-140), a 
bradykinin B2-receptor antagonist (20). Both com-
pounds were able to completely block DXS-induced hy-
potension, whereas only the former compound prevented 
the decrease of uncleaved kininogen. 
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MATERIALS AND METHODS 
D X S and B A Y x 4 6 2 0 
Recombinant BAY x 4620 (7) was generously provided by P. 
Stadler, D. Hörlein, and F. Schumann (Bayer AG, Wuppertal, 
Germany). For these studies, the compound was dissolved in 
sterile physiological saline and infused intravenously. 
DXS, with a molecular mass of —500,000 Da (Pharmacia 
LKB, Uppsala, Sweden), was dissolved in 30 ml of sterile physi-
ological saline 1 h before use and infused intravenously in a 
dose of 5 mg/kg for 1 h. The dose of DXS used in this study was 
based on previous experimentation (9). Animals were observed 
for 2 h from the start of the DXS infusion. 
On the basis of preliminary pharmacokinetic experiments 
(data not shown), the entire dose administered was divided into 
a bolus dose (one-third of the total) injected 15 min before the 
start of the DXS infusion, followed by a continuous infusion 
over 135 min during which time the remaining two-thirds of the 
dose was delivered. The total dose of BAY x 4620 was varied 
from 45 to 360 mg. Three control groups, 1) DXS plus saline, 2) 
saline alone, and 3) high-dose BAY x 4620 (360 mg) alone, were 
also included in this study. 
All animal procedures were approved by the Regierung von 
Oberbayern and complied with the Tierschutzgesetz in der Fas-
sung of August 18,1986. The animals, 35 miniature pigs, were 
fasted overnight but had free access to water. Sedation was 
achieved by azaperone (3 mg/kg im) and metomidate (3.75 mg/ 
kg ip). After induction of anesthesia with pentobarbital sodium 
(24 mg/kg iv), a 6.5-mm orotracheal tube was placed and venti-
lation was maintained by use of a 900C ventilator (Siemens 
Elema AB). Vascular catheters (arterial and central venous, 
Swan-Ganz) and a short large-bore cannula in the external jug-
ular vein were inserted through groin and neck incisions, re-
spectively, for blood sampling. After the preparation, the ani-
mals rested for 1 h. 
Blood pressure was recorded every 5 min with other physio-
logical measurements [e.g., cardiac output (CO) and pulmo-
nary arterial pressure (PAP)] being made every 30 min. Blood 
was collected for biochemical analysis and kinin extraction 
every 15 min. 
Blood sampling and extraction for the kinin measurement 
was based on previously reported procedures (19, 21). Briefly, a 
10-ml plastic syringe was filled with 3 ml of 0.8 M HCl and 
cooled on ice. Through the large-bore cannula in the external 
jugular vein, 5 ml of blood were drawn into the syringe. Care 
was taken to achieve maximum aspiration speed by avoiding 
contact between the tip of the syringe and the vessel wall. Dur-
ing the aspiration the syringe was rotated for the rapid mixing 
of HCl and blood. The sample was then injected immediately 
into a second plastic syringe containing 2 ml of ice-cooled 0.8 N 
HCl, shaken vigorously, and placed on ice. The final pH of the 
sample was adjusted to 2.0 by the addition of 1.15 ml of a 2 N 
NaOH solution. After 3.68 g of NaCl were added to the sample, 
it was mixed in an ice-cooled kinematic inversion shaker (Tur-
bola, Bachofen, Basel, Switzerland) for 10 min. 
For the kinin extraction, 3 ml of n-butanol were added to 
each syringe, and the sample was mixed again for 4 min and 
then centrifuged for 4 min at 1,800 g. The butanol phase was 
separated into an ice-cooled test tube, and the process was re-
peated two more times with the centrifugation period extended 
to 6 and 8 min, respectively. The three butanol fractions were 
pooled, and the cellular debris and residual plasma proteins 
were discarded. For the removal of lipids and simultaneous 
reextraction of kinins into an aqueous medium, 1.5 ml of petro-
leum ether and 2 ml of distilled water were added to the butanol 
extracts, and the solution was mixed in the shaker for 10 min 
and then centrifuged at 800 g for 14 min. The aqueous phase 
was then transferred into Eppendorf tubes with a glass Pasteur 
pipette, frozen, and stored at -80°C for subsequent assay. 
Plasma levels of uncleaved kininogen were measured by al-
lowing trypsin to degrade any high- and low-molecular-mass 
kininogen contained in the sample, with subsequent measure-
ment of the released kinin (22, 24). 
The assay of the kinin levels in the blood as well as the mea-
surement of kinin produced from intact kininogen in the 
plasma (see above) utilized a double-antibody radioimmunoas-
say (21). The antikinin antibody was from K. Shimamoto (Sap-
poro, Japan). The second antibody, anti-rabbit globulin from 
the donkey, was purchased from IDS (Tyne and Wear, UK). 
The detection limit for kinin using this technique is 30 fmol/ml. 
The anaphylatoxin C3a was measured as des-Arg-C3a, a 
stable and biologically inactive degradation product of C3a pro-
duced by carboxypeptidase B. A modified radioimmunoassay 
was used (22) based on a method described for human des-Arg-
C3a (12) with the antiserum against des-Arg-C3a raised in rab-
bits. des-Arg-C3a and antiserum against des-Arg-C3a were 
gifts from the late B. Damerau (Göttingen, Germany). The fi-
brin monomer in plasma was measured with an enzyme immu-
noassay based on a monoclonal antibody (23). This antibody 
binds to the NH2-terminal end of the a-chain of porcine fibrin. 
Thrombin cleavage of known amounts of fibrinogen was used 
to prepare the standard curve used in the assay. 
D X S and H o e - 1 4 0 
Six weaned domestic pigs with a body weight ranging from 
26 to 34 kg were used in this study. Anesthesia, ventilation, and 
surgical procedure were the same as described above. All ani-
mals received DXS (2 mg/kg) as a continuous infusion over 60 
min. Three animals were randomized to receive a bolus injec-
tion of Hoe-140 (30 pg/kg body wt) 10 min before the start of 
the DXS infusion. Hoe-140 was a gift from B. A. Schoelkens 
and K. J. Wirth, Hoechst AG, Frankfurt, Germany. Three con-
trol animals received a saline injection instead of Hoe-140. The 
dose of Hoe-140 was chosen on the basis of preliminary inhibi-
tion experiments with bolus injections of bradykinin as well as 
pilot experiments with DXS (data not shown). The dose chosen 
for this study was found to completely block the hypotensive 
response to bolus injections of bradykinin up to 2,000 ng/injec-
tion; the threshold dose needed to produce a decrease of 3-5 
mmHg in diastolic blood pressure was 10-20 ng of bradykinin 
before the administration of Hoe-140. CO was measured every 
5 min with the thermodilution method; arterial and venous 
pressures in the systemic and pulmonary circulations were re-
corded simultaneously. Systemic vascular resistance (SVR) 
was calculated by using a standard formula {79.9[mean arterial 
blood pressure (MABP) - central venous pressure]/CO}. To-
tal protein was measured with the Biuret method. 
Statistical Analysis 
Unless otherwise noted, data are presented as means ± SE. 
The level of significance was chosen as a = 0.05. 
The evaluation of the blood pressure changes produced by 
DXS had to take into account that administration of the lower 
doses of the inhibitor only delayed the time of onset of DXS-in-
duced hypotension and that complete inhibition would occur 
only at higher doses. Therefore, for each individual experi-
ment, we measured the time after the start of the DXS infusion 
at which the blood pressure had fallen to <60% of the baseline 
value. These data were analyzed with the Mantel-Haenszel 
test. The software program that was used (TEST, Institut fur 
Datenanalyse und Versuchsplanung, Gauting, Germany) simul-
taneously performed multiple Scheffé-like comparisons be-
tween the groups. 
Furthermore, the distribution of the measurements of un-
cleaved kininogen was not normal and the baseline levels were 
not equal in all groups. Here, the time from start of the DXS 
infusion to a 50% decrease of the uncleaved kininogen level was 
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FIG. 1. Effects of dextran sulfate (DXS) and plasma kallikrein inhibitor BAY x 4620 over time. Miniature pigs 
received DXS infusion (5 mg/kg iv) for 1 h plus either saline solution or BAY x 4620 in doses of 45, 90,180, or 360 mg 
over 2 h (5 groups) or received saline solution alone (1 group). A : early decrease of mean arterial blood pressure 
(MABP; % of baseline value) in control group was delayed by low doses of inhibitor, attenuated by higher dose, and 
completely prevented by highest dose (P < 0.001). B : DXS alone produced biphasic rise in pulmonary arterial pressure 
(PAP) at 10 and 60 min. Secondary rise in PAP was attenuated by high doses of inhibitor (P = 0.0017). C: kinin-con-
taining kininogen in plasma is given as % of baseline value. Early decrease in kininogen in control group was delayed by 
low and higher doses of inhibitor and blocked by highest dose (P < 0.001). D: release of kinin was attenuated with 
increasing doses of inhibitor and completely blocked by highest dose (P < 0.0015). E : anaphylatoxin des-Arg-C3a (C3a) 
in plasma is given as % of baseline value. C3a in plasma rose to reach maximum at 1 h in control group. Formation of 
C3a was attenuated with increased doses of inhibitor (P < 0.05). F: in group that received DXS alone, fibrin rose 
substantially. Higher doses of inhibitor produced partial inhibition, with highest dose producing complete inhibition of 
fibrin formation (P < 0.05). 
measured in each animal and analyzed with the aforemen-
tioned procedure (Mantel-Haenszel test). 
The distribution of the measurements of kinin also was not 
normal, but, in this case, the Kruskall-Wallis analysis of ranks 
was used. For a global test, the average of all repeated measure-
ments during DXS infusion in each animal was formed. Multi-
ple tests at each time were decided according to the closure 
principle (16). 
For a global test of PAP, the average of the repeated measure-
ments during DXS infusion in each animal was formed. These 
values were analyzed by analysis of covariance, with the base-
line measurement as covariate. Multiple comparisons between 
groups were made with Tukey's test. Because of their distribu-
tion, results of des-Arg-C3a and fibrin were analyzed with 
Kruskall-Wallis analysis. A global value could not be formed 
because of missing values. Therefore, the multiple niveau alpha 
was ascertained with a modified Bonferroni procedure (10). For 
the data involving DXS and Hoe-140, the statistical analysis 
was limited to a comparison at 25 min, the time of maximum 
blood pressure decrease. The Mann-Whitney U test was used 
with P < 0.05 considered significant. 
R E S U L T S 
D X S and B A Y x 4 6 2 0 
M A B P (Fig. 1). DXS (5 mg/kg) induced a rapid decline 
in MABP that reached a nadir of 44.5 ± 2.6% of baseline 
value at 15 min in the group DXS + NaCI. MABP re-
turned to normal levels by 30 min after the DXS infusion 
was started. In the group that received DXS and the low-
est dose of BAY x 4620 (DXS + 45 mg of BAY x 4620), 
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FIG. 2. Effects of DXS and Hoe-140 over time. Six weaned pigs re-
ceived DXS infusion iv (2 mg/kg) for 1 h. In addition, 3 pigs received 30 
Mg/kg of Hoe-140 (•) 15 min before DXS and 3 pigs received saline 
solution (O). Time course in each group is presented as mean ± SE. 
jc-Axis, time after onset of DXS infusion. A : control animals had sharp 
decrease in MABP from 15 to 35 min after onset of DXS infusion, 
whereas Hoe-140-treated animals had completely stable blood pres-
sure; their MABP was significantly higher at 25 min. B : systemic vascu-
lar resistance (SVR) is given as % of baseline value. Arterial hypoten-
sion in control animals was paralleled by systemic vasodilation, 
whereas Hoe-140-treated animals had stable SVR; their SVR was sig-
nificantly higher at 25 min. C: cardiac output (CO) is given as % of 
baseline value. From 5 to 30 min after onset of DXS infusion, CO was 
elevated in control animals. Hoe-140-treated animals had unchanged 
CO (NS). D : heart rate (HR) is given as % of baseline value. Control 
animals responded with rise in HR to DXS infusion. Hoe-140-treated 
animals had no change in HR (NS). E : values of uncleaved kininogen 
declined to 18 ± 1% of baseline without any difference between groups. 
F: values of total protein remained stable. 
MABP remained stable until 20 min, decreased to its 
nadir of 45 ± 3.5% after 30 min, and then returned to 
baseline level. The augmented dose of the inhibitor (DXS 
+ 90 mg of BAY x 4620) led to a further delay in the onset 
of hypotension that reached its nadir of 46 ± 4.8% at 45 
min. The next inhibitor dose level (DXS + 180 of mg 
BAY x 4620) not only delayed the onset but also reduced 
the magnitude of hypotension to 78 ± 10% at 55 min. 
MABP remained constant during the entire observation 
period in the group with DXS and the highest inhibitor 
dose (DXS + 360 mg of BAY x 4620) and in the control 
group without DXS. The time to 60% hypotension dif-
fered significantly between the groups (Mantel-Haenszel 
test, P < 0.001), and in the multiple comparison test, the 
difference between DXS + NaCl and DXS + 360 mg of 
BAY x 4620 was statistically significant (P < 0.001). 
P A P (Fig. 1). PAP displayed a biphasic rise to 118 ± 
11% at 10 min and 198 ± 13% at 55 min in response to the 
DXS infusion. Administration of BAY x 4620 delayed or 
attenuated only the second PAP increase, with the group 
receiving DXS + 360 mg of BAY x 4620 snowing an early 
rise to 120% of baseline value but no secondary peak. The 
groups were significantly different in the global test 
(mean value during DXS infusion, analysis of covari-
ance, P = 0.0017), but multiple between-group compari-
sons did not reveal a significant difference between DXS 
+ NaCl and DXS + 360 mg of BAY x 4620. All multiple 
tests over time were significant from 35 to 90 min. 
C i r c u l a t i n g kininogen (Fig. 1). In the group DXS + 
NaCl, uncleaved kininogen in plasma decreased to 54 ± 
19% at 15 min and to 21 ± 1% at 30 min and remained 
around 20 ± 1% of baseline value for the remainder of the 
study. This decrease in uncleaved kininogen was delayed 
by the simultaneous administration of BAY x 4620; in 
the group DXS + 180 mg of BAY x 4620, kininogen de-
creased to 30 ± 10% at 60 min. In the group with the 
highest dose of the inhibitor, DXS + 360 mg of BAY x 
4620, and in the group without DXS, no decrease in kin-
inogen was observed. The time to 50% kininogen de-
crease differed significantly between the groups (Man-
tel-Haenszel test, P < 0.001). The difference between 
DXS + NaCl and DXS + 360 mg of BAY x 4620 was 
statistically significant (multiple Scheffé-like compari-
sons, P < 0.02). 
F r e e k i n i n (Fig. 1). Kinin levels in blood as a function of 
time corresponded closely with the changes seen in 
MABP. BAY x 4620 produced a dose-dependant delay in 
the release of kinin with increasing doses while also pro-
gressively reducing the amplitude of kinin release. In the 
group with the highest inhibitor dose, DXS + 360 mg of 
BAY x 4620, only two of five animals had kinin levels 
above the detection limit, the highest being 47 fmol/ml. 
The group without DXS had no detectable kinin release. 
The global test as well as all multiple tests for repeated 
measurements during the infusion of DXS revealed a 
statistically significant difference between the groups (P 
< 0.002). The comparison between the groups DXS + 
NaCl and DXS + 360 mg of BAY x 4620 was significant 
(P < 0.02). 
Complement activation (Fig. 1). The plasma concentra-
tion of des-Arg-C3a rose to three times baseline value at 
60 min in the group DXS + NaCl. All groups except the 
control group without DXS showed such an increase, 
with a peak at 60 min followed by a slow decline. The 
peak of des-Arg-C3a flattened when the dose of the inhib-
itor increased. Except for baseline measurements, at 
each time the difference between the groups was statisti-
cally significant, and the global test was significant 
(Hommel's multiple test, P < 0.05). 
F i b r i n monomer (Fig. 1). Fibrin monomer in plasma 
increased steadily during the 2-h observation period, 
with peak levels of 39 ± 7 /ig/ml being reached at 2 h in 
the group DXS + NaCl. Except for the control group 
without DXS administration, all groups had an increase 
in fibrin monomer that showed a dose-dependent reduc-
tion based on the amount of inhibitor. The difference 
between the groups was statistically significant at each 
time and in the global test (P < 0.05). It must be noted, 
however, that at the baseline value there was a marginal 
difference between the groups (P = 0.051). 
D X S and H o e - 1 4 0 (Fig. 2) 
The control animals in this study experienced severe 
arterial hypotension similar to that seen in Fig. 1 A . DXS 
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(2 mg/kg) induced a rapid decline in MABP that reached 
a nadir of 51 ± 8% of baseline value at 25 min. MABP 
returned to baseline values at 40 min. In the Hoe-140-
treated group MABP remained completely stable. These 
groups were significantly different (P < 0.05). 
The arterial hypotension of the control animals was 
paralleled by a decrease in SVR. SVR decreased to 40 ± 
6% at 25 min and was restored to baseline levels at 40 
min. The Hoe-140-treated group did not experience this 
vasodilation, with the difference being statistically signif-
icant (P < 0.05). 
Hypotension and vasodilation were accompanied by 
rises in cardiac output and heart rate (HR). In the con-
trol animals, CO rose to 134 ± 25% at 25 min and re-
turned to baseline values at 40 min, and HR rose to 150 ± 
40% at 25 min and returned to baseline values at 45 min. 
Both effects appeared to be prevented in the Hoe-140-
treated group, but the differences were not statistically 
significant. 
Uncleaved kininogen decreased to 18% with no appar-
ent difference between the groups, whereas total protein 
remained stable in both groups. 
DISCUSSION 
The principal finding in this study was that both BAY 
x 4620, a plasma kallikrein inhibitor, and Hoe-140, a bra-
dykinin B2-receptor antagonist, prevented DXS-induced 
hypotension in pigs. 
DXS infusion produced all the effects that would be 
predicted, assuming that it is an activator of the contact 
system. At 15 min, very high kinin concentrations in 
blood were found, which closely correlated with a brisk 
decrease in arterial blood pressure. Uncleaved kininogen 
decreased and reached a steady-state level at 30 min, 
whereas anaphylatoxin C3a increased, reaching a peak at 
60 min. Fibrin monomer also increased continuously 
during the observation period. These data corroborate 
our assumption that activation of the contact system had 
taken place as a consequence of the infusion of DXS. 
DXS infusion also produced alterations in lung func-
tion, particularly a transient increase in mean PAP. 
Other parameters of lung function, such as extravascular 
lung water and airway pressure, however, showed only 
minor changes (data not shown). One possible explana-
tion for the increase in PAP is the activation of thrombin 
because thrombin is a potent pulmonary vasoconstrictor 
(11). However, our data do not rule out other causes of 
the PAP rise. 
Administration of BAY x 4620 before and during DXS 
infusion delayed or attenuated the DXS-induced 
changes, with the highest dose producing a complete 
blockade of the DXS-induced changes measured in this 
system. 
Compared with natural aprotinin from bovine lungs, 
BAY x 4620, the mutant that was employed in our study, 
is a relatively potent and selective plasma kallikrein in-
hibitor with an inhibitor constant for human plasma kal-
likrein roughly 100-fold lower than that of natural apro-
tinin. The inhibitor constants of BAY x 4620 for human 
plasma kallikrein and human plasmin are 5 X 10"10 and 2 
X 10~10 M, respectively, whereas the corresponding val-
ues of wild-type aprotinin are 3 X 10"8 and 8 X 10"11 M 
(W. Schröder, Bayer AG Pharmaceutical Research, 
Wuppertal, Germany, personal communication). 
In this regard, it is important to note that plasma lev-
els of BAY x 4620 were in the range of 1.5 when 
a complete blockade of DXS-induced changes was 
achieved (data not shown). In previous experiments, a 
complete blockade of DXS-induced hypotension was 
only achieved with plasma concentrations of wild-type 
aprotinin —12.5 p M (9). This indicates that BAY x 4620 
is also a far better inhibitor of plasma kallikrein than 
natural aprotinin when used in vivo. As a result, this 
compound may be useful as a probe to investigate patho-
logical conditions, such as hypotension and bleeding dur-
ing extracorporeal circulation and hemodialysis and he-
reditary angioedema, that are based on activation of the 
contact system. 
The parallels between in vitro and in vivo potencies of 
the two inhibitors aprotinin and BAY x 4620 support the 
notion that DXS-induced hypotension was mediated by 
bradykinin, a peptide that is released after the specific 
cleavage of high-molecular-weight kininogen by plasma 
kallikrein. 
Bradykinin is one of the most potent hypotensive 
agents yet described. The finding that the effect of DXS 
infusion, namely hypotension, elevated kinin levels in 
the blood and that the decrease of the precursor of bra-
dykinin, uncleaved kininogen, was prevented by the 
plasma kallikrein inhibitor BAY x 4620 gives support to 
the notion that the decrease in blood pressure was me-
diated by the release of bradykinin. However, other va-
soactive mediators such as prostacyclin, platelet-activat-
ing factor, or serotonin can be released either directly by 
DXS or indirectly via thrombin or bradykinin and could 
also be responsible for all or part of the response. We 
therefore wanted to determine whether the blockade of 
bradykinin B 2 receptors alone would prevent DXS-in-
duced hypotension. 
In the second part of this study, we studied the effect of 
the B2-receptor antagonist Hoe-140 on DXS-induced hy-
potension. In this study, DXS infusion also led tran-
siently to severe arterial hypotension that was accompa-
nied by vasodilation and increases in HR and CO in the 
control animals, whereas Hoe-140 completely blocked 
these effects in the treated group. However, serial mea-
surements of uncleaved kininogen demonstrate that ef-
fective activation of the contact system had taken place 
equally in both groups. Total protein measurements 
were unchanged in both groups, making specific cleavage 
the likely cause for the decrease in kininogen. The rela-
tively small sample size in this study was selected on the 
basis of pilot experiments that indicated that the actual 
dose of Hoe-140 used in this study would completely 
block bradykinin-induced hypotension. The finding that 
the bradykinin receptor blockade with Hoe-140 com-
pletely abolished DXS-induced hypotension once more 
points to bradykinin as the primary causative mediator. 
In summary, we have shown that DXS infusion in pigs 
produces activation of the contact system of blood coagu-
lation with the following consequences: the appearance 
of high kinin levels in blood; a decrease in uncleaved kin-
inogen in plasma; severe transient arterial hypotension 
2680 KININ GENERATION IN VIVO BY DEXTRAN SULFATE INFUSION 
accompanied by vasodilation and a compensatory rise in 
CO and HR; and activation of the coagulation, comple-
ment, and fibrinolysis cascades. Both the plasma kal-
likrein inhibitor BAY x 4620 and the bradykinin B 2 re-
ceptor antagonist Hoe-140 were able to block DXS-
induced hypotension. Only the former compound 
prevented the decrease of uncleaved kininogen, whereas 
the latter compound prevented hypotension during on-
going kininogen cleavage. We conclude that DXS infu-
sion led to the release of bradykinin from kininogen via 
activation of the contact system and led to arterial hypo-
tension via stimulation of the B 2 kinin receptor. 
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